1,714
Views
0
CrossRef citations to date
0
Altmetric
Clinical Study

The association of plasma NT-proBNP level and progression of diabetic kidney disease

, , , , , , , , & ORCID Icon show all
Article: 2158102 | Received 28 Mar 2022, Accepted 05 Dec 2022, Published online: 23 Feb 2023

References

  • Saran R, Robinson B, Abbott KC, et al. US kidney data system 2016 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2017;69(3 Suppl 1):A7–A8.
  • Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302–308.
  • Saran R, Li Y, Robinson B, et al. US kidney data system 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2015;66: S1–S305.
  • Hall C. NT-proBNP: the mechanism behind the marker. J Card Fail. 2005;11(5 Suppl): S81–S83.
  • Idzerda NMA, Persson F, Pena MJ, et al. N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-kidney response to aliskiren in patients with type 2 diabetes at high kidney and cardiovascular risk. Diabetes Obes Metab. 2018;20(12):2899–2904.
  • Welsh P, Woodward M, Hillis GS, et al. Do cardiac biomarkers NT-proBNP and hsTnT predict microvascular events in patients with type 2 diabetes? Results from the ADVANCE trial. Diabetes Care. 2014;37(8):2202–2210.
  • Anderson AH, Xie D, Wang X, et al. Novel risk factors for progression of diabetic and nondiabetic CKD: findings from the chronic kidney insufficiency cohort (CRIC) study. Am J Kidney Dis. 2021;77(1):56–73.
  • Fiorentino M, Bolignano D, Tesar V, et al. Kidney biopsy in patients with diabetes: a pooled meta-analysis of 48 studies. Nephrol Dial Transplant. 2017;32(1):97–110.
  • Pinsker JE, Shank T, Dassau E, et al. Comment on American diabetes association. Approaches to glycemic treatment. Sec. 7. In standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl. 1):S41–S48.
  • An Y, Xu F, Le W, et al. Kidney histologic changes and the outcome in patients with diabetic nephropathy. Nephrol Dial Transplant. 2015;30(2):257–266.
  • Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):556–563.
  • Li L, Zhang X, Li Z, et al. Kidney pathological implications in type 2 diabetes mellitus patients with kidney involvement. J Diabetes Complications. 2017;31(1):114–121.
  • Yancy CW, Jessup M, Bozkurt B, et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–e161. 2017.
  • Wang J, Wang L, Jin L, et al. Predictive value of MPV and plasma NT-proBNP combined with the simplified Geneva scale for the prognosis of acute pulmonary embolism. Evid Based Complement Alternat Med. 2021;2021:1292921. 2021.
  • Ostermann M, Bellomo R, Burdmann EA, Conference Participants, et al. Controversies in acute kidney injury: conclusions from a kidney disease: improving global outcomes (KDIGO) conference. Kidney Int. 2020;98(2):294–309.
  • Hu W, Zhou PH, Wang W, et al. Prognostic value of adrenomedullin and natriuretic peptides in uroseptic patients induced by ureteroscopy. Mediators Inflamm. 2016;2016:9743198. 2016.
  • Chen F, Li JQ, Ou YW, et al. The impact of kidney function on the prognostic value of N-terminal pro-B-type natriuretic peptide in patients with coronary artery disease. Cardiol J. 2019;26(6):696–703.
  • Michels WM, Grootendorst DC, Verduijn M, et al. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol. 2010;5(6):1003–1009.
  • Hoshino J, Mise K, Ueno T, et al. A pathological scoring system to predict kidney outcome in diabetic nephropathy. Am J Nephrol. 2015;41(4–5):337–344.
  • Mottl AK, Gasim A, Schober FP, et al. Segmental sclerosis and extracapillary hypercellularity predict diabetic ESKD. J Am Soc Nephrol. 2018;29(2):694–703.
  • Colhoun HM, Marcovecchio ML. Biomarkers of diabetic kidney disease. Diabetologia. 2018;61(5):996–1011.
  • Zhou L, Cai X, Li M, et al. Plasma NT-proBNP is independently associated with albuminuria in type 2 diabetes. J Diabetes Complications. 2016;30(4):669–674.
  • Seki N, Matsumoto T, Fukazawa M. Relationship between the brain natriuretic peptide (BNP) level and prognosis of diabetic nephropathy with microalbuminuria: a 7-year follow-up study. Horm Metab Res. 2018;50(5):389–396.
  • Saulnier PJ, Gand E, Velho G, SURDIAGENE Study Group, et al. Association of circulating biomarkers (adrenomedullin, TNFR1, and NT-proBNP) with kidney function decline in patients with type 2 diabetes: a French prospective cohort. Diabetes Care. 2017;40(3):367–374.
  • Bansal N, Katz R, Dalrymple L, et al. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults. Clin J Am Soc Nephrol. 2015;10(2):205–214.
  • Malachias MVB, Jhund PS, Claggett BL, et al. NT-proBNP by itself predicts death and cardiovascular events in high-risk patients with type 2 diabetes mellitus. J Am Heart Assoc. 2020;9(19):e017462.
  • Zhang X, Zhou Y, Ma R. Potential effects and application prospect of angiotensin receptor-neprilysin inhibitor in diabetic kidney disease. J Diabetes Complications. 2022;36(1):108056.
  • Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018.
  • Tsai YC, Tsai HJ, Lee CS, et al. The interaction between N-terminal pro-brain natriuretic peptide and fluid status in adverse clinical outcomes of late stages of chronic kidney disease. PLOS One. 2018;13(8):e0202733.
  • Desai AS, Toto R, Jarolim P, et al. Association between cardiac biomarkers and the development of ESKD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis. 2011;58(5):717–728.
  • Zou Y, Zhao L, Zhang J, et al. Development and internal validation of machine learning algorithms for end-stage kidney disease risk prediction model of people with type 2 diabetes mellitus and diabetic kidney disease. Ren Fail. 2022;44(1):562–570.
  • Cheng Y, Shang J, Liu D, et al. Development and validation of a predictive model for the progression of diabetic kidney disease to kidney failure. Ren Fail. 2020;42(1):550–559.
  • Sun L, Shang J, Xiao J, et al. Development and validation of a predictive model for end-stage kidney disease risk in patients with diabetic nephropathy confirmed by kidney biopsy. PeerJ. 2020;8:e8499.
  • Schefold JC, Filippatos G, Hasenfuss G, et al. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016;12(10):610–623.
  • Szymanski MK, de Boer RA, Navis GJ, et al. Animal models of cardiokidney syndrome: a review. Heart Fail Rev. 2012;17(3):411–420.
  • KDIGO. Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98:S1–S115. 2020.